STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
Cosimo Lobello, Boris Tichý, Vojtěch Bystrý, Lenka Radová, Daniel Filip, Marek Mráz, Ivonne A. Montes‐Mojarro, Nina Prokoph, Hugo Larose, Huan-Chang Liang, Geeta G. Sharma, Luca Mologni, David Belada, Kateřina Kamarádová, Falko Fend, Carlo Gambacorti‐Passerini, Olaf Merkel, Suzanne D. Turner, Andrea Janíková, Šárka Pospı́šilová
Abstract
Systemic Anaplastic Large Cell Lymphoma (sALCL) encompasses two distinct clinical entities of T-cell non-Hodgkin lymphoma: Anaplastic Lymphoma Kinase-positive (ALK+) ALCL and ALK-negative (ALK-) ALCL. These entities are characterized by either the presence or absence of an ALK-translocation. It has been reported that ALK+ ALCL has a better prognosis compared to ALK-, with a 5-year overall survival (OS) of 70-80% versus 15-45%(1,2). Furthermore, more than 30% of ALK+ ALCL patients relapse(3,4). Despite the distinction between the two sALCL subtypes, frontline treatment for adults is similar and is based on CHOP or CHOEP(5,6). Whilst high-throughput genomic studies in sALCL have shown recurrent genetic alterations, their association with outcome has not been fully investigated(7–11).